Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Long-Term Debt Repayments (2018 - 2024)

Mimedx (MDXG) has disclosed Long-Term Debt Repayments for 3 consecutive years, with $30.0 million as the latest value for Q1 2024.

  • Quarterly Long-Term Debt Repayments changed N/A to $30.0 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $30.0 million through Dec 2024, changed N/A year-over-year, with the annual reading at $30.0 million for FY2024, N/A changed from the prior year.
  • Long-Term Debt Repayments hit $30.0 million in Q1 2024 for Mimedx, up from $1000.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $30.0 million in Q1 2024 to a low of $30.0 million in Q1 2024.